Application of MST1R inhibitor and JMJD6 inhibitor in preparation of medicine for treating gallbladder cancer

Through the combination of MST1R inhibitor MGCD-265 and JMJD6 inhibitor SKLB325, the problem of unclear targets and drug resistance in gallbladder cancer treatment was solved, significantly improved the sensitivity of gallbladder cancer cells, and provided a new therapeutic strategy. It extends patient survival and reduces drug resistance.

CN118903139APending Publication Date: 2024-11-08王伟
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410878288.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The causes and pathogenesis of gallbladder cancer are not fully elucidated, and the existing targeted treatment targets are unclear, resulting in limited treatment options and poor treatment effects in patients with gallbladder cancer, and high drug resistance to targeted therapy, which affects patient survival and treatment. Effect.

Method used

The combined preparation of MST1R inhibitor MGCD-265 and JMJD6 inhibitor SKLB325 was used to inhibit the proliferation and in vivo growth of gallbladder cancer cells, reduce the content of CDK4 and CDK6, induce cell apoptosis and cell cycle arrest, and achieve anti-tumor effects.

Benefits of technology

It significantly improves the sensitivity of gallbladder cancer cells, enhances the anti-gallbladder cancer effect, provides new targeted therapy strategies, extends the patient's survival, reduces the possibility of targeted therapy to produce drug resistance, and fills in the existing technology blank.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903139A_ABST
    Figure CN118903139A_ABST
Patent Text Reader

Abstract

The invention belongs to but not limited to the technical field of medicines, and discloses application of combination of an MST1R inhibitor MGCD-265 and a JMJD6 inhibitor SKLB325 in preparation of a medicine for treating gallbladder cancer. The combination of the MST1R inhibitor and JMJD6 inhibition can generate a stronger effect of resisting gallbladder cancer. A potential candidate drug is provided for research and development of anti-tumor drugs for the gallbladder cancer, and a potential combined treatment strategy is provided for clinical treatment of the gallbladder cancer. The application of the medicine is helpful for increasing the treatment selection of gallbladder cancer patients and increasing the total five-year survival rate of the gallbladder cancer patients; the treatment effect of gallbladder cancer patients is improved through combined use of multi-target drugs, the life quality of the patients is improved, and the development of the health level of the masses is promoted; a new strategy and candidate drugs are provided for clinically improving treatment of human gallbladder cancer, the anti-gallbladder effect is enhanced, and the possibility of drug resistance in targeted treatment of gallbladder cancer is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to but is not limited to the field of medical technology, and in particular relates to the use of a MST1R inhibitor MGCD-265 and a JMJD6 inhibitor SKLB325 in combination to prepare a drug for treating gallbladder cancer. Background Art

[0002] Gallbladder cancer (GBC) is the most common type of malignant tumor of the gallbladder and bile duct. Although its overall incidence is low, its mortality rate is high. Due to the asymptomatic nature of gallbladder cancer during its initial development and its tendency to rapidly metastasize in the early stages, as well as its difficulty in detection and diagnosis, most patients are already in the late stages of the disease when diagnosed, and less than 20% of gallbladder cancer patients meet the conditions for potentially curative surgical resection at the time of diagnosis. Most GBC patients find it difficult to achieve clinical cure, and even if they undergo radical surgical resection, the risk of tumor recurrence is still more than 65%, and the overall 5-year survival rate is less than 5%. To date, the cause and pathogenesis of gallbladder cancer have not been fully elucidated.

[0003] Current studies have shown that factors associated with the development of gallbladder cancer include gender, geographic location, race, congenital malformations, gallstones, obesity, and gallbladder inflammation. However, in general, the causes and pathogenesis of gallbladder cancer have not been fully elucidated. In recent years, single nucleotide polymorphism (SNP) association studies have identified potential genetic variations associated with the development of gallbladder cancer, which provide potential targets for the treatment of gallbladder cancer. For example, ABCG8 and TRAF3 genes are significantly associated with gallbladder cancer. In addition, gene variations or changes in related protein content in inflammation, apoptosis, DNA repair, drug metabolism, hedgehog signaling and Wnt signaling, TGF-β and MET-related pathways are also significantly associated with the occurrence and development of gallbladder cancer.

[0004] The above-mentioned gene variation information provides key insights into the pathogenesis of GBC, and also reveals precise strategies for the prevention and targeted treatment of gallbladder cancer, which is expected to develop new target drugs for gallbladder cancer. The expression product of MET is a tyrosine kinase, which is upregulated in a variety of tumor tissues including gallbladder cancer. The use of MET inhibitors can significantly inhibit the proliferation, migration and invasion of gallbladder cancer cells. At the same time, MET's homolog MST1R is also upregulated in a variety of tumors, and can co-activate the downstream FAK pathway to promote the proliferation of tumor cells.

[0005] At present, small molecule inhibitors targeting MST1R and MET have been verified in preclinical studies and clinical trials. However, whether these small molecule inhibitors have anti-gallbladder cancer effects has not been confirmed. Therefore, finding new small molecule chemotherapeutic drugs targeting gallbladder cancer will help increase the treatment options for gallbladder cancer patients and improve the clinical treatment effect of gallbladder cancer.

[0006] The difficulty and significance of solving the above technical problems:

[0007] (1) Exploring new small molecule chemotherapeutic drugs targeting gallbladder cancer will help increase the treatment options for gallbladder cancer patients and improve the overall 5-year survival rate of gallbladder cancer patients.

[0008] (2) Exploring the mechanism of action of targeted therapy for gallbladder cancer will help clarify the relevant molecular mechanisms of tumor targeted inhibition and provide new strategies and targets for clinical improvement of gallbladder cancer treatment resistance. However, the target of targeted inhibition of gallbladder cancer is not clear at present. Solving this problem will help improve the treatment effect of gallbladder cancer patients through the combined use of multi-target drugs, improve the quality of life of patients, and promote the development of public health and well-being.

[0009] (3) Exploring the effects of the combined use of the MST1R small molecule inhibitor MGCD-265 and the JMJD6 inhibitor SKLB325 will help provide new strategies and candidate drugs for clinical improvement of the treatment of human gallbladder cancer, enhance the anti-gallbladder effect, and reduce the possibility of resistance to targeted treatment of gallbladder cancer. Summary of the invention

[0010] In view of the problems existing in the prior art, the present invention provides an application of a MST1R inhibitor MGCD-265 combined with a JMJD6 inhibitor SKLB325 to prepare a drug for treating gallbladder cancer.

[0011] The present invention is achieved by combining the MST1R inhibitor MGCD-265 with the JMJD6 inhibitor SKLB325 to prepare a drug for treating gallbladder cancer.

[0012] Furthermore, the gallbladder cancer is gallbladder cancer of different species.

[0013] Furthermore, the gallbladder cancer cells are GBC-SD, NOZ, or SGC-996 cells.

[0014] Furthermore, the mouse gallbladder cancer is induced by GBC-SD cells.

[0015] Furthermore, the Q values ​​of MGCD-265 combined with SKLB325 for gallbladder cancer cells GBC-SD, NOZ, and SGC-996 were all greater than 1.15.

[0016] Furthermore, the combination of MST1R inhibitor and JMJD6 inhibitor reduced the in vitro proliferation ability of GBC-SD, NOZ, SGC-996 cells and other gallbladder cancer cells.

[0017] Furthermore, the combination of MST1R inhibitor and JMJD6 inhibitor reduced the in vivo growth ability of gallbladder cancer cells GBC-SD.

[0018] Furthermore, the combination of MST1R inhibitor and JMJD6 inhibitor reduced the levels of CDK4 and CDK6.

[0019] Furthermore, the drug includes an MST1R inhibitor, a JMJD6 inhibitor and a pharmaceutically acceptable carrier.

[0020] Furthermore, the medicine is an oral or injectable preparation.

[0021] Another object of the present invention is to provide the use of the MST1R inhibitor MGCD-265 alone in the preparation of a drug for treating gallbladder cancer.

[0022] MST1R inhibitors inhibit the proliferation of GBC-SD, NOZ, SGC-996 cells and other gallbladder cancer cells in vitro, achieving antitumor effects by inducing apoptosis and cell cycle arrest.

[0023] MGCD-265 can reduce the levels of CDK4 and CDK6 and increase the level of Cleaved caspase3.

[0024] MST1R inhibitors can inhibit the proliferation of GBC-SD gallbladder cancer cells in vivo and achieve anti-tumor effects by inducing cell apoptosis and cell cycle arrest.

[0025] MST1R inhibitors mainly produce anti-tumor effects by inhibiting the expression of downstream genes such as AKT2 and AKT3.

[0026] MST1R inhibitors can significantly upregulate the expression of CDK2AP1 and CDKN1A, and significantly downregulate the expression of MMP2, MMP26, etc.

[0027] In combination with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solutions to be protected by the present invention are as follows:

[0028] First, the present invention provides the use of the MST1R inhibitor MGCD-265 and the JMJD6 inhibitor SKLB325 in combination to prepare a drug for treating gallbladder cancer. The MST1R inhibitor provided by the present invention mainly produces an anti-tumor effect by inhibiting the expression of its downstream genes, such as MMP family members or PI3K pathway-related genes. In addition, the combination of MST1R inhibitor and JMJD6 inhibition can produce a stronger anti-gallbladder cancer effect; it provides a potential candidate drug for the development of gallbladder cancer anti-tumor drugs and a potential combined treatment strategy for the clinical treatment of gallbladder cancer.

[0029] The present invention provides a method for treating gallbladder cancer by combining an MST1R inhibitor, MGCD-265, and a JMJD6 inhibitor, SKLB325. The method can be safely and effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully demonstrate the therapeutic effect of the method, and are expected to develop an effective and safe therapeutic drug for gallbladder cancer. The application of the drug helps to (1) increase the treatment options for gallbladder cancer patients and improve the overall 5-year survival rate of gallbladder cancer patients. (2) Improve the treatment effect of gallbladder cancer patients by combining the use of multi-target drugs, improve the quality of life of patients, and promote the development of the public's health level. (3) Provide new strategies and candidate drugs for clinical improvement of the treatment of human gallbladder cancer, enhance the anti-gallbladder effect, and reduce the possibility of resistance to targeted treatment of gallbladder cancer.

[0030] Second, as auxiliary evidence of the inventiveness of the claims of the present invention, it is also reflected in the following important aspects:

[0031] (1) The expected benefits and commercial value of the technical solution of the present invention after transformation are:

[0032] There are 220,000 new cases of gallbladder cancer and 165,000 deaths worldwide. In China, there are about 53,000 new cases and 41,000 deaths each year. After conversion, this patent is expected to provide cutting-edge targeted treatment measures for gallbladder cancer patients, and is expected to generate significant commercial value each year. Currently, there are about 53,000 patients suffering from gallbladder cancer in China each year. These patients are the indication population for this patent invention. Calculated based on the annual use of RMB 10,000 per patient, the annual commercial value is about RMB 500 million.

[0033] (2) The technical solution of the present invention fills the technical gap in the industry at home and abroad:

[0034] The invention provides a method for treating gallbladder cancer by combining an MST1R inhibitor MGCD-265 with a JMJD6 inhibitor SKLB325, which is expected to develop an effective and safe therapeutic drug for gallbladder cancer. There are currently no related reports at home and abroad, which fills the technical gap in the industry at home and abroad and has good innovation.

[0035] (3) The technical solution of the present invention solves the technical problems that people have been eager to solve but have never been able to solve successfully:

[0036] Gallbladder cancer is the most common type of malignant tumor of the gallbladder and bile duct, and its overall mortality rate is high. Due to the asymptomatic nature of gallbladder cancer during its initial development and its tendency to rapidly metastasize in the early stages, most patients are already in the advanced stages of the disease when diagnosed, and less than 20% of gallbladder cancer patients meet the conditions for potentially curative surgical resection at the time of diagnosis. Targeted therapy provides a potential treatment option for the treatment of gallbladder cancer. The present invention provides a combination of an MST1R inhibitor MGCD-265 and a JMJD6 inhibitor SKLB325 for the treatment of gallbladder cancer, which helps (1) increase the treatment options for gallbladder cancer patients and improve the overall 5-year survival rate of gallbladder cancer patients. (2) Improve the treatment effect of gallbladder cancer patients by combining the use of multi-target drugs, improve the quality of life of patients, and promote the development of the public's health and well-being. (3) Provide new strategies and candidate drugs for clinical improvement of human gallbladder cancer treatment, enhance anti-gallbladder effects, and reduce the possibility of resistance to targeted treatment of gallbladder cancer, which is expected to solve the clinical treatment problems that people have always desired but have never been able to break through.

[0037] (4) The technical solution of the present invention overcomes technical prejudice:

[0038] Previous targeted therapies have been less used in gallbladder cancer and lack clear targets. This project screened the clear target MST1R for gallbladder cancer through high-throughput sequencing, and explored the anti-gallbladder cancer effect of its targeted inhibitor MGCD-265. At the same time, by combining with the JMJD6 inhibitor SKLB325 to improve the therapeutic effect of gallbladder cancer, it is expected to overcome the clinical treatment resistance of gallbladder cancer. It has good logic and overcomes technical bias to a certain extent. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 It is a diagram of gene expression of paracancerous tissue and cancerous tissue in gallbladder cancer analyzed by a network database provided by an embodiment of the present invention;

[0040] Figure 2 is a KEGG analysis diagram of differentially expressed genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0041] Figure 3 is a GO analysis (BP) diagram of differentially expressed genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0042] Figure 4 is a GO analysis (MF) diagram of differentially expressed genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0043] Figure 5 is a GO analysis (CC) diagram of differentially expressed genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0044] Figure 6is a PPI analysis diagram of differentially expressed genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0045] Figure 7 is a KEGG analysis diagram of up-regulated genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0046] Figure 8 It is a GO analysis (BP) diagram of up-regulated genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0047] Fig. 9 is a GO analysis (MF) diagram of up-regulated genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0048] Fig.10 is a GO analysis (CC) diagram of up-regulated genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0049] Fig.11 is a KEGG analysis diagram of down-regulated genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0050] Fig.12 is a GO analysis (BP) diagram of down-regulated genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0051] Fig.13 is a GO analysis (MF) diagram of down-regulated genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0052] Fig.14 is a GO analysis (CC) diagram of down-regulated genes in gallbladder cancer tissue provided by an embodiment of the present invention;

[0053] Fig.15 It is a relative transcription level diagram of related genes analyzed based on a network database provided by an embodiment of the present invention;

[0054] Fig.16 This is a diagram showing the effect of MGCD-265 on the proliferation ability of gallbladder cancer GBC-SD cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0055] Fig.17 This is a diagram showing the effect of MGCD-265 on the proliferation ability of gallbladder cancer NOZ cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0056] Fig.18 This is a diagram showing the effect of MGCD-265 on the proliferation ability of gallbladder cancer SGC-996 cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0057] Fig.19This is a diagram showing the effect of 0.2 μM, 0.8 μM, and 3.2 μM MGCD-265 on the clone formation ability of gallbladder cancer GBC-SD, NOZ, and SGC-996 cells in a clone formation experiment provided in an embodiment of the present invention;

[0058] Fig. 20 This is a diagram showing the effect of AMRUBICIN on the proliferation ability of gallbladder cancer GBC-SD cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0059] Fig.21 This is a diagram showing the effect of HESPERADIN on the proliferation ability of gallbladder cancer GBC-SD cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0060] Fig. 22 This is a diagram showing the effect of HYDROXYUREA on the proliferation ability of gallbladder cancer GBC-SD cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0061] Fig.23 This is a diagram showing the effect of PF-03814735 on the proliferation ability of gallbladder cancer GBC-SD cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0062] Fig.24 This is a diagram showing the effect of AZD-4877 on the proliferation ability of gallbladder cancer GBC-SD cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0063] Fig.25 This is a diagram showing the effect of ILORASERTIB on the proliferation ability of gallbladder cancer GBC-SD cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0064] Fig.26 This is a diagram showing the effect of VOLASERTIB on the proliferation ability of gallbladder cancer GBC-SD cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0065] Fig. 27 This is a diagram showing the effect of AMRUBICIN on the proliferation of gallbladder cancer NOZ cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0066] Fig.28 This is a diagram showing the effect of HESPERADIN on the proliferation ability of gallbladder cancer NOZ cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0067] Fig.29 This is a diagram showing the effect of HYDROXYUREA on the proliferation ability of gallbladder cancer NOZ cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0068] Fig.30This is a diagram showing the effect of PF-03814735 on the proliferation ability of gallbladder cancer NOZ cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0069] Fig.31 This is a diagram showing the effect of ILORASERTIB on the proliferation ability of gallbladder cancer NOZ cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0070] Fig.32 This is a diagram showing the effect of AZD-4877 on the proliferation ability of gallbladder cancer NOZ cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0071] Fig.33 This is a diagram showing the effect of VOLASERTIB on the proliferation ability of gallbladder cancer NOZ cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0072] Fig.34 This is a diagram showing the effect of AMRUBICIN on the proliferation ability of gallbladder cancer SGC-996 cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0073] Fig.35 This is a graph showing the effect of HESPERADIN on the proliferation ability of gallbladder cancer SGC-996 cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0074] Fig.36 This is a diagram showing the effect of HYDROXYUREA on the proliferation ability of gallbladder cancer SGC-996 cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0075] Fig.37 This is a diagram showing the effect of PF-03814735 on the proliferation ability of gallbladder cancer SGC-996 cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0076] Fig.38 This is a diagram showing the effect of ILORASERTIB on the proliferation ability of gallbladder cancer SGC-996 cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0077] Fig.39 This is a diagram showing the effect of AZD-4877 on the proliferation ability of gallbladder cancer SGC-996 cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0078] Fig.40 This is a diagram showing the effect of VOLASERTIB on the proliferation ability of gallbladder cancer SGC-996 cells detected by the CCK-8 method provided in an embodiment of the present invention;

[0079] Fig.41This is a graph showing the effect of 0.2 μM, 0.8 μM, and 3.2 μM MGCD-265 on the cell cycle distribution of gallbladder cancer GBC-SD, NOZ, and SGC-996 cells detected by flow cytometry provided in an embodiment of the present invention;

[0080] Fig.42 This is a statistical result diagram of the cell cycle distribution of gallbladder cancer GBC-SD cells at 0.2 μM, 0.8 μM, and 3.2 μM MGCD-265 provided in an embodiment of the present invention;

[0081] Fig.43 This is a statistical result diagram of the effect of 0.2 μM, 0.8 μM, and 3.2 μM MGCD-265 on the cell cycle distribution of gallbladder cancer NOZ cells provided in the embodiment of the present invention;

[0082] Fig.44 This is a statistical result diagram of the cell cycle distribution of gallbladder cancer SGC-996 cells at 0.2 μM, 0.8 μM, and 3.2 μM MGCD-265 provided in an embodiment of the present invention;

[0083] Fig.45 It is a representative diagram of Western blot detection of the content of cell cycle-related proteins in gallbladder cancer GBC-SD cells after treatment with different concentrations of MGCD-265 provided in the embodiment of the present invention;

[0084] Fig.46 It is a statistical result diagram of the protein content related to the cell cycle of gallbladder cancer GBC-SD cells after being treated with different concentrations of MGCD-265 by Western blotting provided in an embodiment of the present invention;

[0085] Fig.47 This is a graph showing the effect of 0.2 μM, 0.8 μM, and 3.2 μM MGCD-265 on apoptosis of gallbladder cancer GBC-SD, NOZ, and SGC-996 cells detected by flow cytometry provided in an embodiment of the present invention;

[0086] Fig.48 It is a statistical result diagram of the apoptosis ratio of gallbladder cancer GBC-SD cells by 0.2 μM, 0.8 μM and 3.2 μM MGCD-265 provided in the embodiment of the present invention;

[0087] Fig.49 It is a statistical result diagram of the apoptosis ratio of gallbladder cancer NOZ cells by 0.2 μM, 0.8 μM and 3.2 μM MGCD-265 provided in the embodiment of the present invention;

[0088] Fig.50 It is a statistical result diagram of the apoptosis ratio of gallbladder cancer SGC-996 cells by 0.2 μM, 0.8 μM and 3.2 μM MGCD-265 provided in the embodiment of the present invention;

[0089] Fig.51 It is a representative diagram of the Western blot detection of the apoptosis-related protein content of gallbladder cancer GBC-SD cells after treatment with 0.2 μM, 0.8 μM, and 3.2 μM MGCD-265 provided in the embodiment of the present invention;

[0090] Fig.52 It is a statistical result diagram of apoptosis-related protein content of gallbladder cancer GBC-SD cells after treatment with 0.2 μM, 0.8 μM, and 3.2 μM MGCD-265 provided in an embodiment of the present invention by Western blotting;

[0091] Fig.53 It is a statistical result diagram of the growth of subcutaneous tumors after treatment with 5 mg / kg and 10 mg / kg of MGCD-265 provided in the embodiment of the present invention;

[0092] Fig.54 It is a representative picture of the growth of subcutaneous tumors after treatment with 5 mg / kg and 10 mg / kg of MGCD-265 provided in the examples of the present invention;

[0093] Fig.55 This is a statistical result diagram of the effect of 5 mg / kg and 10 mg / kg MGCD-265 treatment on the body weight of tumor-bearing mice provided in the examples of the present invention;

[0094] Fig.56 It is a representative picture of the Western blot detection of the content of cell cycle and apoptosis-related proteins in tumor-bearing mice after treatment with 5 mg / kg and 10 mg / kg of MGCD-265 provided in the embodiment of the present invention;

[0095] Fig.57 This is a statistical result diagram of the protein content related to cell cycle and apoptosis in tumor-bearing mice after treatment with 5 mg / kg and 10 mg / kg of MGCD-265 provided in an embodiment of the present invention by Western blotting;

[0096] Fig.58 This is an immunohistochemical staining diagram of cleaved caspase3, CDK4, and CDK6 of tumor nodules after treatment with 5 mg / kg and 10 mg / kg of MGCD-265 provided in an embodiment of the present invention;

[0097] Fig.59 This is a diagram showing the effect of 5 mg / kg and 10 mg / kg MGCD-265 treatment on the liver pathological condition of tumor-bearing mice, as provided by an embodiment of the present invention;

[0098] Fig.60 This is a diagram showing the effect of 5 mg / kg and 10 mg / kg MGCD-265 treatment on the renal pathological condition of tumor-bearing mice, as detected by HE staining provided in an embodiment of the present invention;

[0099] Fig.61 It is a graph showing the number of differentially expressed genes in gallbladder cancer GBC-SD cells affected by 0.8 μM MGCD-265 treatment as detected by transcriptomic sequencing provided by an embodiment of the present invention;

[0100] Fig.62 It is a differential gene volcano plot showing the effect of 0.8 μM MGCD-265 treatment on gene expression in gallbladder cancer cells provided in an embodiment of the present invention;

[0101] Fig.63 This is a differential gene heat map showing the effect of 0.8 μM MGCD-265 treatment on gene expression in gallbladder cancer cells provided in an embodiment of the present invention;

[0102] Fig.64 This is a graph showing the effect of 0.8 μM MGCD-265 treatment on the expression of genes downstream of the MST1R gene provided in an embodiment of the present invention;

[0103] Fig.65 This is a graph showing the effect of 0.8 μM qPCR method provided in an embodiment of the present invention on the gene expression of gallbladder cancer cells;

[0104] Fig.66 It is a GO analysis bar graph of differentially expressed genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0105] Fig.67 It is a bubble chart of GO analysis enrichment of differentially expressed genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0106] Fig.68 This is a KEGG analysis bar graph of differentially expressed genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0107] Fig.69 It is a bubble chart of KEGG analysis enrichment of differentially expressed genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0108] Fig.70 It is a GO analysis bar graph of down-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0109] Fig.71 It is a bubble chart of GO analysis enrichment of down-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0110] Fig.72 This is a KEGG analysis bar graph of down-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0111] Fig.73 It is a bubble chart of KEGG analysis enrichment of down-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0112] Fig.74 It is a GO analysis bar graph of up-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0113] Fig.75 It is a bubble chart of GO analysis enrichment of up-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0114] Fig.76 It is a KEGG analysis bar graph of up-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0115] Fig.77 It is a bubble chart of KEGG analysis enrichment of up-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265 provided in an embodiment of the present invention;

[0116] Fig.78 It is a graph of relative transcription levels of 30 genes with the largest up-regulated amplitude in transcriptomic sequencing verified by qPCR method provided in an embodiment of the present invention;

[0117] Fig.79 It is a schematic diagram of the combined drug target screening process and a statistical result diagram of the drug interaction Q value provided by an embodiment of the present invention;

[0118] Fig.80 This is a graph showing the effect of MGCD-265 combined with SKLB325 on the proliferation ability of gallbladder cancer GBC-SD cells provided in an embodiment of the present invention;

[0119] Fig.81 This is a graph showing the effect of MGCD-265 combined with SKLB325 on the proliferation ability of gallbladder cancer NOZ cells provided in an embodiment of the present invention;

[0120] Fig.82 This is a graph showing the effect of MGCD-265 combined with SKLB325 on the proliferation ability of gallbladder cancer SGC-996 cells provided in an embodiment of the present invention;

[0121] Fig.83This is an immunohistochemical staining diagram of JMJD6, CDC25A, HSP90AA1, SLC7A11 and SLC1A5 in tumor tissues of subcutaneous tumor-bearing mice treated with 10 mg / kg of MGCD-265 provided in an embodiment of the present invention;

[0122] Fig.84 This is a graph showing the effect of MGCD-265 combined with NVP-BEP800 on the proliferation ability of gallbladder cancer GBC-SD cells provided in an embodiment of the present invention;

[0123] Fig.85 This is a graph showing the effect of MGCD-265 combined with NVP-BEP800 on the proliferation ability of gallbladder cancer NOZ cells provided in an embodiment of the present invention;

[0124] Fig.86 This is a graph showing the effect of MGCD-265 combined with NVP-BEP800 on the proliferation ability of gallbladder cancer SGC-996 cells provided in an embodiment of the present invention;

[0125] Fig.87 This is a graph showing the effect of MGCD-265 combined with HG106 on the proliferation ability of gallbladder cancer GBC-SD cells provided in an embodiment of the present invention;

[0126] Fig.88 This is a graph showing the effect of MGCD-265 combined with HG106 on the proliferation ability of gallbladder cancer NOZ cells provided in an embodiment of the present invention;

[0127] Fig.89 This is a graph showing the effect of MGCD-265 combined with HG106 on the proliferation ability of gallbladder cancer SGC-996 cells provided in an embodiment of the present invention;

[0128] Fig.90 This is a graph showing the effect of MGCD-265 combined with V-9302 on the proliferation ability of gallbladder cancer GBC-SD cells provided in an embodiment of the present invention;

[0129] Fig.91 This is a graph showing the effect of MGCD-265 combined with V-9302 on the proliferation ability of gallbladder cancer NOZ cells provided in an embodiment of the present invention;

[0130] Fig.92 This is a graph showing the effect of MGCD-265 combined with V-9302 on the proliferation ability of gallbladder cancer SGC-996 cells provided in an embodiment of the present invention;

[0131] Fig.93 This is a graph showing the effect of MGCD-265 combined with NSC95397 on the proliferation ability of gallbladder cancer GBC-SD cells provided in an embodiment of the present invention;

[0132] Fig.94This is a graph showing the effect of MGCD-265 combined with NSC95397 on the proliferation ability of gallbladder cancer NOZ cells provided in an embodiment of the present invention;

[0133] Fig.95 This is a graph showing the effect of MGCD-265 combined with NSC95397 on the proliferation ability of gallbladder cancer SGC-996 cells provided in an embodiment of the present invention;

[0134] Fig.96 This is a statistical result diagram of the growth of subcutaneous tumors in tumor-bearing mice after treatment with 5 mg / kg of MGCD-265 combined with 5 mg / kg of SKLB325 provided in an embodiment of the present invention;

[0135] Fig.97 This is a representative diagram of the growth of subcutaneous tumors in tumor-bearing mice after treatment with 5 mg / kg of MGCD-265 combined with 5 mg / kg of SKLB325 provided in the examples of the present invention;

[0136] Fig.98 This is a statistical result diagram of the subcutaneous tumor volume of tumor-bearing mice after being treated with 5 mg / kg of MGCD-265 combined with 5 mg / kg of SKLB325 provided in an embodiment of the present invention;

[0137] Fig.99 This is a graph showing the effect of 5 mg / kg of MGCD-265 combined with 5 mg / kg of SKLB325 on the body weight of tumor-bearing mice provided in an embodiment of the present invention;

[0138] Fig.100 This is an immunohistochemical staining image of CDK4 and CDK6 in tumor nodules of tumor-bearing mice treated with 5 mg / kg of MGCD-265 combined with 5 mg / kg of SKLB325 provided in an embodiment of the present invention;

[0139] Fig.101 This is a diagram showing the effect of 5 mg / kg of MGCD-265 combined with 5 mg / kg of SKLB325 on the liver pathological condition of tumor-bearing mice as detected by HE staining provided in an embodiment of the present invention;

[0140] Fig.102 This is a graph showing the effect of 5 mg / kg of MGCD-265 combined with 5 mg / kg of SKLB325 on the renal pathological condition of tumor-bearing mice detected by HE staining provided in an embodiment of the present invention. DETAILED DESCRIPTION

[0141] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0142] 1. Cell sources and culture conditions

[0143] Human gallbladder cancer cell lines GBC-SD, NOZ, and SGC-996 were provided by the Shanghai Cell Bank of the Chinese Academy of Sciences. GBC-SD, NOZ, and SGC-996 cells were cultured in a mixture of 89% RPMI1640 medium + 10% fetal bovine serum + 1% penicillin-streptomycin. These cells were cultured in a cell culture incubator at 37°C, containing 5% CO2 and saturated humidity. Cells in the logarithmic growth phase were used for subsequent experimental determinations.

[0144] 2.CCK-8 Experiment

[0145] GBC-SD, NOZ, and SGC-996 cells in the logarithmic growth phase were inoculated into 96-well plates (100 μL / well) at a density of 2×103 cells / well. After the cells adhered to the wall, the original culture medium was discarded and fresh culture medium containing different concentrations of drugs was added. Five replicate wells were set up for each group, and a group of blank controls was set up at the same time. Continue to culture for 24 hours, discard the culture medium, and add 100 μL of CCK-8 preparation mixed culture medium to each well. Place in an incubator and incubate for 4 hours. Use an enzyme reader to measure the absorbance value (OD) at a wavelength of 450nm to calculate cell viability and IC50.

[0146] 3. Colony formation experiment

[0147] GBC-SD, NOZ, and SGC-996 cells in the logarithmic growth phase were digested with 0.25% trypsin and blown into single cells. Single cell suspensions were made with cell culture medium and inoculated in 6-well plates at a density of 400 cells / well. Three replicate wells were set up in each group and treated with different concentrations of MGCD-265 for 10 days. The cell culture plates were washed 2-3 times with PBS, then fixed with 4% paraformaldehyde for 1 hour and stained with Giemsa dye for 30 minutes at room temperature. The number of cell clones was counted and photographed for preservation.

[0148] 4. Cell cycle assay

[0149] The suspension of gallbladder cancer cells in the logarithmic growth phase was inoculated in a six-well plate and treated with different concentrations of MGCD-265 for 24 hours. The adherent cells were obtained by trypsin digestion and prepared into a cell suspension, which was then fixed in pre-cooled 70% ethanol overnight at 4°C. The cells were centrifuged at 4°C to precipitate the cells, the ethanol was removed, the cells were washed twice with cold PBS and resuspended, 100μL RnaseA (1mg / mL) and 400μL propidium iodide (PI) staining buffer were added, and the cells were incubated at 4°C in the dark for 30min, washed twice with cold PBS and resuspended, and then the cell cycle distribution was detected using a flow cytometer.

[0150] 5. Cell apoptosis experiment

[0151] Gallbladder cancer cell suspension (1.0×105 cells / well) in the logarithmic growth phase was inoculated in a 24-well plate and treated with different concentrations of MGCD-265. Three replicate wells and a group of blank controls were set up, and the cells were cultured for 24 hours. The adherent cells and cells in the supernatant were obtained by trypsin digestion and prepared into a cell suspension. 300μL Binding Buffer was added to resuspend the cells at 4℃, and 5μL Annexin V and 5μL PI were added respectively, and incubated at room temperature in the dark for 20min. Cell apoptosis in each group was detected by flow cytometry within 1h.

[0152] 6. Western Blotting

[0153] GBC-SD cells were treated with different concentrations of MGCD-265 for 24 h, and RIPA lysis buffer containing protease inhibitor PMSF was added. The cells were lysed on ice for 30 min, and then centrifuged at 4°C, 12000xg for 15 min, and the supernatant was collected. The protein concentration was measured by the BCA method. Gel electrophoresis was performed using a 10% SDS-PAGE separation gel, and an equal amount of protein (30 μg) was loaded for each sample. After electrophoresis, the proteins on the gel were transferred to a PVDF membrane using a wet transfer method. The PVDF membrane was blocked with a blocking buffer containing 5% skim milk for 2 h at room temperature. The corresponding primary antibody (1:2000 dilution) was added at 4°C and incubated overnight. After washing three times with TBST, the membrane was incubated with the corresponding secondary antibody (1:4000 dilution) for 2 h at room temperature. The protein bands were detected using an ECL luminescence kit, and protein quantitative analysis was performed using Image J software. The β-actin band was used as an internal reference and the sample loading amount was unified.

[0154] 7. RNA Extraction, Reverse Transcription and qRT-PCR

[0155] After treating the cells with the corresponding drugs as above, the cell culture plates were washed with pre-cooled PBS, and total RNA of the cell samples was extracted using TRIzol (Invitrogen Life Technologies, USA). After measuring the RNA concentration using a NanoDrop spectrophotometer, the RNA was reverse transcribed into cDNA using a reverse transcription kit according to the instructions, and qRT-PCR was performed using a LightCycler 96 fluorescence quantitative PCR instrument. The transcript of β-actin was used as an internal reference to unify the sample loading amount. The relative transcription level of the target gene was statistically analyzed using 2-ΔΔCT.

[0156] 8. Animal sources and rearing conditions

[0157] Female BALB / c nude mice (6 weeks old, weighing 16-18 g) were housed under specific pathogen-free conditions with constant temperature (23 ± 2 °C) and controlled light (12 h light: 12 h dark). All experiments were performed in accordance with relevant guidelines and regulations.

[0158] 9. Nude mouse subcutaneous xenograft tumor experiment

[0159] After GBC-SD cells were cultured to the logarithmic growth phase as described above, they were prepared into a suspension and inoculated subcutaneously on the outside of the right hind limb of BALB / c nude mice. The inoculation volume was 100 μL and the inoculation amount was 2×106 cells / mouse. When the tumor volume grew to about 100 mm3, the mice were randomly divided into a control group, a low-dose MGCD-265 group (5 mg / kg), and a high-dose MGCD-265 group (10 mg / kg). Oral administration, 100 μL / mouse. Tumor size and body weight were measured once every 3 days. On the 28th day after treatment, the mice were killed by cervical dislocation, and the tumors were removed and fixed in formalin.

[0160] 10. HE staining experiment

[0161] Fresh tissues were fixed in 4% paraformaldehyde (PFA) for 24 h, dehydrated with graded concentrations of ethanol, and embedded in paraffin. The tissues were sliced ​​at a thickness of 6 μM, and then the paraffin sections were stained with hematoxylin and eosin (H&E). The pathological structures were observed under an optical microscope (Olympus, Japan) and photographed for preservation.

[0162] 11. Immunohistochemistry (IHC) experiment

[0163] After dewaxing and rehydration, the paraffin sections prepared above were immersed in citrate buffer (pH = 6) for 10 minutes for antigen repair. Endogenous peroxidase was then inactivated with 3% hydrogen peroxide solution and washed three times with PBS. Blocked with 3% bovine serum albumin for 30 minutes, then added with primary antibody and incubated overnight at 4°C. After washing with PBS, the secondary antibody was added and incubated at room temperature for 1 hour, and DAB was used as the color developing solution for color development. Hematoxylin was used for counterstaining to display the cell nucleus. After dehydration and sealing, the staining positivity was observed under an optical microscope (Olympus, Japan) and photographed for preservation.

[0164] 12. Total RNA Isolation, Library Preparation, and RNA Transcriptomics Sequencing

[0165] Cells were seeded in six-well plates and treated with MGCD-265. Total RNA was isolated from cells using TRIzol reagent according to the manufacturer's protocol, and the quality of the extracted total RNA samples was measured using a spectrophotometer. The purity of the total RNA samples was assessed based on the absorbance ratio at 260 nm and 280 nm, and a ratio between 1.8 and 2.0 was considered acceptable. Total RNA with an RNA integrity number (RIN) ≥ 7 was used for library preparation. Stranded mRNA Library Prep Kit (Illumina, USA) was used to prepare RNA sequencing libraries. The libraries were then used for paired-end sequencing using the HiSeq X sequencing platform (Illumina, USA). The RPKM values ​​of the transcripts and the ratio of the transcripts were used to calculate the total RPKM value of each gene.

[0166] 13.GO analysis and KEGG analysis

[0167] GO functional annotation analysis is a common method for large-scale functional enrichment studies of genes, including biological process (BP), molecular function (MF) and cellular component (CC) analysis. KEGG is a widely used database for analyzing information on related genomes, biological pathways, diseases and drugs. Genes were enriched according to their pathways, and DEGs were analyzed for GO and KEGG using the R package "clusterProfiler".

[0168] 14. Calculation of Q value of drug synergy

[0169] After the drug intervention test was performed as described above, the inhibition rate was calculated using the following formula: inhibition rate = (1-experimental group OD / control group OD)) × 100%. The half inhibitory concentration (IC50) was calculated using Origin Pro 50.7 software (OriginLab, Massachusetts, USA). In order to evaluate the synergistic effect of MGCD-265 and SKLB325, the formula was used to evaluate whether the in vitro combined cell killing effect of the drugs was synergistic. The Q value was calculated according to the King formula: Q = E (A + B) / (EA + EB-EA × EB), where E (A + B) is the inhibition rate of combined drug use, and EA and EB are the inhibition rates of drug A and drug B, respectively. Q = 0.85-1.15 is a simple addition of the effects of the two drugs, Q greater than 1.15 is enhancement (or synergy), and Q less than 0.85 is antagonism.

[0170] 15. Text mining based on network database

[0171] The transcriptome dataset of gallbladder cancer with the data number GSE74948 was downloaded from the NCBI GEO database, with a total of 6 samples, including 3 cancer tissue samples and 3 normal tissue samples. At the same time, the corresponding platform annotation file was downloaded to convert the probe to gene symbol. For different probes corresponding to the same gene symbol, the average value was taken as the expression value of the gene. The linear regression and empirical Bayes method provided by the limma package were used to perform differential expression analysis on the genes, and the P value and logFC value corresponding to the gene were obtained. The differential expression threshold was set to P value<0.05&|logFC|>2, and the clusterProfilter package was used to perform GO and KEGG enrichment analysis on the differentially expressed genes. At the same time, GO and KEGG analysis were also performed on the up-regulated and down-regulated genes, and the protein-protein interaction relationship of the differentially expressed genes was obtained by using the human protein-protein interaction relationship in the online tool STRING database. The minimum interaction requirement score of the parameter value was 0.9.

[0172] 16. Construction of protein-protein interaction network

[0173] The STRING database is a database that can be used to retrieve known proteins and predicted protein interactions, containing results from experimental data, text mining results from PubMed abstracts, results from other databases, and results predicted using bioinformatics methods. We used the STRING database to select differentially expressed genes (DEGs) with a combined score of more than 400 to construct an mRNA-related protein-protein interaction network (PPI) and visualized the data using Cytoscape (version 3.6.1).

[0174] 17. Analysis of drug-genomic interaction database

[0175] The DGIdb database is a drug-gene interaction database that provides information on the association between genes and their known or potential drugs. In order to screen potential drugs for gallbladder cancer, the DGIdb database was used to screen key target genes for potential candidate drugs or small molecule inhibitors.

[0176] 18. Statistical Analysis

[0177] All data are presented as mean ± standard deviation (SD), and each experiment was repeated at least 3 times. All data calculations and statistical analyses were performed using SPSS 22.0. Between the two groups, independent Student's t test was used for comparison. Differences between multiple groups were analyzed by one-way analysis of variance (ANOVA). P values ​​< 0.05 were considered statistically significant.

[0178] The technical effects of the present invention are:

[0179] 1. The anti-tumor effects of 8 small molecule inhibitors screened based on the pharmacogenomics-related action database were analyzed by CCK-8 method. The results showed that the 8 small molecule inhibitors had different degrees of inhibitory effects on the proliferation of GBC-SD, NOZ, and SGC-996 cells, among which 3 gallbladder cancer cells were more sensitive to the MST1R inhibitor MGCD-265. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0180] 2. The biological effects of MGCD-265 were tested by clone formation experiments. The results showed that MGCD-265 could inhibit the clone formation ability of three types of gallbladder cancer cells in a dose-dependent manner. The drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0181] 3. Flow cytometry was used to detect the effect of MGCD-265 on cell cycle distribution. The results showed that after treatment with MGCD-265, the G0 / G1 phase distribution of GBC-SD, NOZ, and SGC-996 cells increased significantly, and the G2 / M phase distribution decreased significantly and was dose-dependent, while there was no significant change in the S phase. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0182] 4. The content of GBC-SD cell cycle-related proteins was detected by Western blotting, and it was found that CDK4, Cyclin D1, and Cyclin B1 decreased significantly with the increase of MGCD-265 concentration, and P21 increased significantly with the increase of MGCD-265 concentration. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0183] 5. Flow cytometry was used to detect the effect of MGCD-265 on the apoptosis ratio of GBC-SD, NOZ, and SGC-996 cells. The results showed that after MGCD-265 treatment, the number of viable cells of the three gallbladder cancer cells decreased significantly with the increase of drug concentration, and the proportion of apoptosis increased significantly with the increase of drug concentration. MGCD-265 induced apoptosis of the three cells in a dose-dependent manner. The drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0184] 6. The content of apoptosis-related proteins in GBC-SD cells was detected by Western blotting. The results showed that PARP decreased significantly with the increase of MGCD-265 concentration, Cleaved PARP increased significantly with the increase of MGCD-265 concentration, and the content of Cleaved caspase3, the main executor of cell apoptosis, increased significantly with the increase of MGCD-265 concentration. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0185] 7. Subcutaneous tumor tissues of mice were collected, and the results showed that compared with the control group, 5mg / kg and 10mg / kg of MGCD-265 significantly reduced the diameter and volume of subcutaneous tumors in mice, and inhibited the in vivo growth ability of gallbladder cancer cells in a dose-dependent manner. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0186] 8. The weight of mice was monitored, and the results showed that compared with the control group, the two concentrations of MGCD-265 treatment had no significant effect on the weight of mice. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0187] 9. By detecting the apoptosis and cell cycle-related protein content of GBC-SD cells by Western blotting, it was found that Caspase3 gradually decreased with the increase of MGCD-265 concentration, and Cleaved caspase3 significantly increased with the increase of MGCD-265 concentration; cell cycle-related proteins Cyclin D1 and Cyclin B1 significantly decreased with the increase of MGCD-265 concentration. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application, and it is expected to develop an effective therapeutic drug for gallbladder cancer.

[0188] 10. Collect subcutaneous tumor tissues from mice and perform immunohistochemical staining of Cleaved caspase3, CDK4, and CDK6. The results show that 5mg / kg and 10mg / kg of MGCD-265 can reduce the content of CDK4 and CDK6 and increase the content of Cleaved caspase3. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0189] 11. The liver and kidney tissues of mice were collected, fixed and embedded, and then HE staining was performed. The results showed that MGCD-265 treatment had no significant effect on the liver and kidney pathological conditions of mice. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the safety of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0190] 12. The effect of MGCD-265 treatment on the transcriptome of gallbladder cancer cells was analyzed by transcriptomics. The results showed that the abundance of 200 transcripts increased significantly after MGCD-265 treatment, while the abundance of 883 transcripts decreased significantly. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0191] 13. A heat map cluster analysis was performed on the MGCD-265 treated and untreated groups. The results showed that the MGCD-265 treated and untreated groups had significant distinguishing characteristics. The drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of the application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0192] 14. The effect of MGCD-265 treatment on gene expression in gallbladder cancer cells was verified by qPCR, and the expression pattern of MST1R downstream genes such as AKT2, AKT3 and CDK2AP1 was confirmed to be consistent with the transcriptomic sequencing results. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0193] 15. The differentially expressed genes after MGCD-265 treatment were functionally analyzed by KEGG analysis and GO analysis. GO analysis showed that the differentially expressed genes were mainly enriched in molecular functions such as GO: 0071944cellperiphery. KEGG analysis showed that the differentially expressed genes were mainly enriched in pathways related to Organic Systems such as Protein digestion and absorption, and the pathways in which down-regulated genes and up-regulated genes were mainly enriched were different. This drug can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective therapeutic drug for gallbladder cancer.

[0194] 16. The 21 genes significantly upregulated after MGCD-265 treatment were screened for combined drug use and the drug interaction Q value was calculated. Five related small molecule inhibitors were screened, and the Q value of MGCD-265 combined with SKLB325 for three types of gallbladder cancer cells was greater than 1.15. This drug combination can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application, and it is expected to develop an effective combined treatment drug for gallbladder cancer.

[0195] 17. Subcutaneous tumor tissues of mice were collected. The results showed that the combination of MGCD-265 and SKLB325 significantly reduced the in vivo growth ability of gallbladder cancer cells compared with the single use of MGCD-265 and SKLB325. The combination of the two drugs can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective combination therapy for gallbladder cancer.

[0196] 18. The weight of mice was monitored, and the results showed that MGCD-265 and SKLB325 alone had no significant effect on the weight of mice. Although MGCD-265 combined with SKLB325 could reduce the weight of mice, there was no significant difference. This drug combination can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application, and it is expected to develop an effective combination therapy for gallbladder cancer.

[0197] 19. Subcutaneous tumor tissues of mice were collected and immunohistochemical staining of CDK4 and CDK6 was performed. The results showed that the combination of MGCD-265 and SKLB325 significantly reduced the content of CDK4 and CDK6 compared with the single use of MGCD-265 and SKLB325. The combination of the two drugs can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the therapeutic effect of this application and is expected to develop an effective combined therapeutic drug for gallbladder cancer.

[0198] 20. The liver and kidney tissues of mice were collected, fixed and embedded, and then HE staining was performed. The results showed that MGCD-265 alone, SKLB325 alone, and the combination of the two had no significant effect on the liver and kidney pathological morphology of mice. The combination of drugs can be effectively used in the treatment of gallbladder cancer. The experimental results provided are solid and reliable, which can fully prove the safety of this application and is expected to develop an effective combined treatment drug for gallbladder cancer.

[0199] Figure 1The gene expression of paracancerous tissues and cancerous tissues in gallbladder cancer was analyzed using the network database; transcriptomic analysis of paracancerous tissues and cancerous tissues in gallbladder cancer was performed using the network database. The results showed that a total of 3553 genes had significant changes in expression in gallbladder cancer tissues, of which 1058 genes were significantly upregulated and 2495 genes were significantly downregulated.

[0200] The functions of differentially expressed genes were predicted by KEGG analysis and GO analysis. Figure 2 KEGG analysis of differentially expressed genes in gallbladder cancer tissues; KEGG analysis showed that the differentially expressed genes were mainly enriched in pathways such as Chemokine signaling pathway, Viral protein interaction with cytokine and cytokine receptor, and Amoebiasis.

[0201] Figure 3 GO analysis (BP) of differentially expressed genes in gallbladder cancer tissues; GO analysis showed that in biological process (BP), differentially expressed genes were mainly enriched in pathways such as mitotic nuclear division and cell chemotaxis; Figure 4 GO analysis of differentially expressed genes in gallbladder cancer tissues (MF); in molecular function (MF), differentially expressed genes were mainly enriched in extracellular matrix structural constituent, chemokine activity and other pathways; Figure 5 GO analysis of differentially expressed genes in gallbladder cancer tissue (CC); in the cellular component (CC), the differentially expressed genes were mainly enriched in collagen-containing extracellular matrix, spindle and other pathways.

[0202] Figure 6 This is a PPI analysis of differentially expressed genes in gallbladder cancer tissue. The relationship between the differentially expressed genes in paracancerous tissue and cancer tissue of gallbladder cancer was analyzed through PPI. The results showed that the above differentially expressed genes had significant clustering characteristics.

[0203] KEGG analysis and GO analysis were performed on the up-regulated genes and down-regulated genes in the differentially expressed genes, respectively. The results showed that the up-regulated genes were mainly enriched in pathways such as Cell cycle, while the down-regulated genes were mainly enriched in pathways such as Neuroactive ligand-receptor interaction. Figure 7 This is the KEGG analysis of up-regulated genes in gallbladder cancer tissue. KEGG analysis showed that the up-regulated genes were mainly enriched in pathways such as Cell cycle. Figure 8 GO analysis (BP) of up-regulated genes in gallbladder cancer tissues. GO analysis showed that in biological process (BP), the up-regulated genes were mainly enriched in pathways such as nuclear division. Fig. 9 GO analysis of up-regulated genes in gallbladder cancer tissue (MF). GO analysis showed that in the cellular component (MF), they were mainly enriched in pathways such as microtubulebinding. Fig.10 GO analysis of up-regulated genes in gallbladder cancer tissue (CC). GO analysis showed that in molecular function (CC), the up-regulated genes were mainly enriched in spindle and other pathways.

[0204] Fig.11 This is the KEGG analysis of down-regulated genes in gallbladder cancer tissues. KEGG analysis showed that the down-regulated genes were mainly enriched in pathways such as Neuroactive ligand-receptor interaction. Fig.12 GO analysis (BP) of down-regulated genes in gallbladder cancer tissue. GO analysis showed that in biological process (BP), the down-regulated genes were mainly enriched in pathways such as muscle systemprocess. Fig.13 GO analysis of down-regulated genes in gallbladder cancer tissues (MF). GO analysis showed that in the cellular component (MF), the down-regulated genes were mainly enriched in pathways such as glycosaminoglycanbinding. Fig.14 GO analysis of down-regulated genes in gallbladder cancer tissue (CC). GO analysis showed that in molecular function (CC), the down-regulated genes were mainly enriched in pathways such as collagen-containing extracellular matrix.

[0205] Human gallbladder cancer cell lines GBC-SD, NOZ, and SGC-996 cells were inoculated in a mixture of 89% RPMI1640 medium + 10% fetal bovine serum + 1% penicillin-streptomycin. They were cultured in a cell culture incubator at 37°C, 5% CO2, and saturated humidity. Cells in the logarithmic growth phase were used for subsequent experimental determinations.

[0206] As shown in Table 1, the 10 differentially expressed genes with the largest up-regulated folds were screened through the pharmacogenomics-related effect database, and finally 8 small molecule inhibitors with drug development potential were identified as candidate drugs for gallbladder cancer.

[0207] Table 1 List of genes significantly upregulated in gallbladder cancer and with inhibitors

[0208]

[0209] The transcription levels of these 10 differentially expressed genes were analyzed using online databases, such as Fig.15 As shown, they are significantly upregulated in tumor tissues.

[0210] As shown in Table 2, the anti-tumor effects of these eight small molecule inhibitors were analyzed by CCK-8 method. The results showed that the eight small molecule inhibitors had different degrees of inhibitory effects on the proliferation of GBC-SD, NOZ and SGC-996 cells. Among them, the three gallbladder cancer cells were more sensitive to the effect of MST1R inhibitor MGCD-265. The IC50 values ​​of MGCD-265 for gallbladder cancer GBC-SD, NOZ and SGC-996 cells were all less than 1 μM.

[0211] Table 2 IC50 values ​​of each inhibitor against gallbladder cancer GBC-SD, NOZ, SGC-996 cells

[0212]

[0213] Fig.16 The CCK-8 method was used to detect the effect of MGCD-265 on the proliferation ability of gallbladder cancer GBC-SD cells. The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of MGCD-265 concentration.

[0214] Fig.17 The CCK-8 method was used to detect the effect of MGCD-265 on the proliferation ability of gallbladder cancer NOZ cells. The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of MGCD-265 dose.

[0215] Fig.18 The CCK-8 method was used to detect the effect of MGCD-265 on the proliferation ability of gallbladder cancer SGC-996 cells. The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of MGCD-265 concentration.

[0216] Fig. 20 The CCK-8 method was used to detect the effect of AMRUBICIN on the proliferation ability of gallbladder cancer GBC-SD cells. The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of AMRUBICIN concentration.

[0217] Fig.21 The CCK-8 method was used to detect the effect of HESPERADIN on the proliferation ability of gallbladder cancer GBC-SD cells. The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of HESPERADIN concentration.

[0218] Fig. 22The CCK-8 method was used to detect the effect of HYDROXYUREA on the proliferation ability of gallbladder cancer GBC-SD cells. The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of HYDROXYUREA concentration.

[0219] Fig.23 The CCK-8 method was used to detect the effect of PF-03814735 on the proliferation ability of gallbladder cancer GBC-SD cells. The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of PF-03814735 concentration.

[0220] Fig.24 The CCK-8 method was used to detect the effect of AZD-4877 on the proliferation ability of gallbladder cancer GBC-SD cells. The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of AZD-4877 concentration.

[0221] Fig.25 The CCK-8 method was used to detect the effect of ILORASERTIB on the proliferation ability of gallbladder cancer GBC-SD cells. The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of ILORASERTIB concentration.

[0222] Fig.26 The CCK-8 method was used to detect the effect of VOLASERTIB on the proliferation ability of gallbladder cancer GBC-SD cells. The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of VOLASERTIB concentration.

[0223] Fig. 27 The CCK-8 method was used to detect the effect of AMRUBICIN on the proliferation ability of gallbladder cancer NOZ cells. The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of AMRUBICIN concentration.

[0224] Fig.28 The CCK-8 method was used to detect the effect of HESPERADIN on the proliferation ability of gallbladder cancer NOZ cells. The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of HESPERADIN concentration.

[0225] Fig.29 The CCK-8 method was used to detect the effect of HYDROXYUREA on the proliferation ability of gallbladder cancer NOZ cells. The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of HYDROXYUREA concentration.

[0226] Fig.30 The CCK-8 method was used to detect the effect of PF-03814735 on the proliferation ability of gallbladder cancer NOZ cells. The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of PF-03814735 concentration.

[0227] Fig.31 The CCK-8 method was used to detect the effect of ILORASERTIB on the proliferation ability of gallbladder cancer NOZ cells. The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of ILORASERTIB concentration.

[0228] Fig.32 The CCK-8 method was used to detect the effect of AZD-4877 on the proliferation ability of gallbladder cancer NOZ cells. The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of AZD-4877 concentration.

[0229] Fig.33 The CCK-8 method was used to detect the effect of VOLASERTIB on the proliferation ability of gallbladder cancer NOZ cells. The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of VOLASERTIB concentration.

[0230] Fig.34 The CCK-8 method was used to detect the effect of AMRUBICIN on the proliferation ability of gallbladder cancer SGC-996 cells. The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of AMRUBICIN concentration.

[0231] Fig.35 The CCK-8 method was used to detect the effect of HESPERADIN on the proliferation ability of gallbladder cancer SGC-996 cells. The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of HESPERADIN concentration.

[0232] Fig.36 The CCK-8 method was used to detect the effect of HYDROXYUREA on the proliferation ability of gallbladder cancer SGC-996 cells. The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of HYDROXYUREA concentration.

[0233] Fig.37 The CCK-8 method was used to detect the effect of PF-03814735 on the proliferation ability of gallbladder cancer SGC-996 cells. The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of PF-03814735 concentration.

[0234] Fig.38 The CCK-8 method was used to detect the effect of ILORASERTIB on the proliferation ability of gallbladder cancer SGC-996 cells. The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of ILORASERTIB concentration.

[0235] Fig.39 The CCK-8 method was used to detect the effect of AZD-4877 on the proliferation ability of gallbladder cancer SGC-996 cells. The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of AZD-4877 concentration.

[0236] Fig.40 The CCK-8 method was used to detect the effect of VOLASERTIB on the proliferation ability of gallbladder cancer SGC-996 cells. The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of VOLASERTIB concentration.

[0237] Fig.19 The clone formation experiment was used to detect the effect of 0.2μM, 0.8μM and 3.2μM MGCD-265 on the clone formation ability of gallbladder cancer GBC-SD, NOZ and SGC-996 cells. The biological effect of MGCD-265 was detected by clone formation experiment. The results showed that MGCD-265 could inhibit the clone formation ability of three gallbladder cancer cells, GBC-SD, NOZ and SGC-996, in a dose-dependent manner.

[0238] Figures 41-44 Flow cytometry was used to detect the effects of 0.2μM, 0.8μM, and 3.2μM MGCD-265 on the cell cycle distribution of gallbladder cancer GBC-SD, NOZ, and SGC-996 cells and the statistical results; compared with the control group, after MGCD-265 treatment, the G0 / G1 phase distribution of GBC-SD, NOZ, and SGC-996 cells increased significantly, and the G2 / M phase distribution decreased significantly, and showed concentration dependence, while there was no obvious change in the S phase.

[0239] Figures 45-46 Representative images and statistical results of Western blot detection of the content of cell cycle-related proteins in gallbladder cancer GBC-SD cells after treatment with different concentrations of MGCD-265; compared with the control group, CDK4, Cyclin D1, and Cyclin B1 were significantly decreased with the increase of MGCD-265 concentration, and P21 was significantly increased with the increase of MGCD-265 concentration.

[0240] Figures 47-50 Flow cytometry was used to detect the effects of 0.2μM, 0.8μM, and 3.2μM MGCD-265 on apoptosis of gallbladder cancer GBC-SD, NOZ, and SGC-996 cells and the statistical results; compared with the control group, after treatment with MGCD-265, the number of viable cells of gallbladder cancer GBC-SD, NOZ, and SGC-996 cells decreased significantly with the increase of drug concentration, and the proportion of cell apoptosis increased significantly with the increase of drug concentration. MGCD-265 induced apoptosis of the three cell types in a dose-dependent manner.

[0241] Figure 51-52Representative images and statistical results of Western blot detection of apoptosis-related protein levels in gallbladder cancer GBC-SD cells after treatment with 0.2μM, 0.8μM, and 3.2μM MGCD-265; compared with the control group, PARP significantly decreased with increasing MGCD-265 concentrations, while Cleaved caspase3 and Cleaved PARP significantly increased with increasing MGCD-265 concentrations, and the content of Cleaved caspase3, the main executor of cell apoptosis, significantly increased with increasing MGCD-265 concentrations.

[0242] The inventors inoculated the GBC-SD cell suspension in the logarithmic growth phase into the subcutaneous area of ​​the right hind limb of BALB / c nude mice, with an inoculation volume of 100 μL and an inoculation amount of 2×106 cells / mouse. When the tumor volume grew to about 100 mm3, the mice were randomly divided into a control group, a low-dose MGCD-265 group (5 mg / kg), and a high-dose MGCD-265 group (10 mg / kg). The drug was administered by gavage, 100 μL / mouse. Tumor size and body weight were measured once every 3 days. On the 28th day after treatment, the mice were killed by cervical dislocation, and the tumors were removed and fixed in formalin.

[0243] Collect subcutaneous tumor tissue from mice. Figure 53-54 The statistical results and representative pictures of subcutaneous tumor growth after treatment with 5 mg / kg and 10 mg / kg of MGCD-265 show that compared with the control group, 5 mg / kg and 10 mg / kg of MGCD-265 significantly reduced the diameter and volume of subcutaneous tumors in mice, and inhibited the in vivo growth ability of gallbladder cancer cells in a dose-dependent manner.

[0244] Monitor the body weight of mice. Fig.55 The statistical results of the effect of 5mg / kg and 10mg / kg MGCD-265 treatment on the body weight of tumor-bearing mice show that compared with the control group, the two concentrations of MGCD-265 treatment had no significant effect on the body weight of mice.

[0245] Figure 56-57 Representative pictures and statistical results of protein contents related to cell cycle and apoptosis in tumor-bearing mice after treatment with 5 mg / kg and 10 mg / kg of MGCD-265 by western blotting. The apoptosis and cell cycle-related protein contents of GBC-SD cells were detected by western blotting, and it was found that Caspase3 gradually decreased with the increase of MGCD-265 concentration, and Cleavedcaspase3 increased significantly with the increase of MGCD-265 concentration; cell cycle-related proteins Cyclin D1 and Cyclin B1 decreased significantly with the increase of MGCD-265 concentration.

[0246] Subcutaneous tumor tissues of mice were collected and immunohistochemical staining of Cleaved caspase3, CDK4, and CDK6 was performed. Fig.58 The immunohistochemical staining images of cleaved caspase3, CDK4, and CDK6 in tumor nodules after treatment with 5 mg / kg and 10 mg / kg of MGCD-265 show that 5 mg / kg and 10 mg / kg of MGCD-265 can reduce the levels of CDK4 and CDK6 and increase the level of cleaved caspase3.

[0247] The liver and kidney tissues of mice were collected, fixed and embedded, and then HE staining was performed. Fig.59 It indicates the effect of 5mg / kg and 10mg / kg MGCD-265 treatment on the liver pathological condition of tumor-bearing mice detected by HE staining; Fig.60 HE staining was used to detect the effect of 5 mg / kg and 10 mg / kg MGCD-265 treatment on the renal pathological conditions of tumor-bearing mice; the results showed that MGCD-265 treatment had no significant effect on the liver and kidney pathological conditions of mice.

[0248] The effects of MGCD-265 treatment on the transcriptome of gallbladder cancer cells were analyzed by transcriptomics. Figure 61-62 Transcriptomic sequencing was used to detect the number of differentially expressed genes and the volcano plot of differentially expressed genes in gallbladder cancer GBC-SD cells affected by 0.8 μM MGCD-265 treatment; the results showed that the abundance of 200 transcripts was significantly increased after MGCD-265 treatment, while the abundance of 883 transcripts was significantly decreased.

[0249] Heat map cluster analysis was performed on the MGCD-265 treated and untreated groups. Fig.65 This is a heat map of differential gene expression in gallbladder cancer cells affected by 0.8 μM MGCD-265 treatment; the results showed that the MGCD-265-treated and untreated groups had significant discriminatory features.

[0250] The expression of MST1R downstream genes was analyzed by Fold Change. Fig.64 It shows the effect of 0.8 μM MGCD-265 treatment on the expression of genes downstream of the MST1R gene; it was found that after drug treatment, the expression of CDK2AP1 and CDKN1A was significantly upregulated, and the expression of MMP2, MMP26, etc. was significantly downregulated.

[0251] The effect of MGCD-265 treatment on gene expression in gallbladder cancer cells was verified by qPCR. Fig.65The 0.8 μM qPCR method verified the effect of MGCD-265 treatment on gene expression in gallbladder cancer cells; it confirmed that the expression pattern of MST1R downstream genes such as AKT2, AKT3 and CDK2AP1 was consistent with the transcriptomics sequencing results.

[0252] KEGG analysis and GO analysis were used to analyze the functions of differentially expressed genes after MGCD-265 treatment. Figures 66-67 The GO analysis bar chart and enrichment bubble chart of differentially expressed genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265; GO analysis showed that the differentially expressed genes were mainly enriched in molecular functions such as GO: 0071944 cell periphery. Figures 68-69 The KEGG analysis bar chart and enrichment bubble chart of differentially expressed genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265. KEGG analysis showed that the differentially expressed genes were mainly enriched in Organic Systems-related pathways such as Protein digestion and absorption, and the pathways in which the down-regulated genes and up-regulated genes were mainly enriched were different.

[0253] Figure 70-71 GO analysis bar chart and enrichment bubble chart of down-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265; the down-regulated genes were mainly enriched in muscle systemprocess and other pathways in BP, collagen-containing extracellular matrix and other pathways in CC, and glycosaminoglycanbinding and other pathways in MF.

[0254] Figure 72-73 KEGG analysis bar chart and enrichment bubble chart of down-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265; the down-regulated genes were mainly enriched in pathways such as Neuroactive ligand-receptor interaction.

[0255] Figure 74-75 The GO analysis bar chart and enrichment bubble chart of up-regulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8 μM MGCD-265; the up-regulated genes were mainly enriched in pathways such as nuclear division in BP, mainly enriched in pathways such as spindle in CC, and mainly enriched in pathways such as microtubule binding in MF.

[0256] Figures 76-77This is the KEGG analysis bar chart and enrichment bubble chart of upregulated genes in gallbladder cancer GBC-SD cells after treatment with 0.8μM MGCD-265; the upregulated genes are mainly enriched in pathways such as Cell cycle.

[0257] The relative transcription levels of the top 30 genes upregulated in transcriptomic sequencing were verified by qPCR. Fig.78 As shown, it was found that the expression of 21 genes including HSPA1A and HSPA1B were significantly upregulated, while 9 genes including HSPD1 had no significant changes.

[0258] like Fig.79 As shown, the above 21 genes were screened for combined drug use and the drug interaction Q value was calculated. Five related small molecule inhibitors were screened, and the Q value of MGCD-265 combined with SKLB325 for three types of gallbladder cancer cells was greater than 1.15. The combination of MGCD-265 and SKLB325 has a stronger anti-tumor effect.

[0259] Subcutaneous tumor tissues of mice were collected and immunohistochemical staining of JMJD6, CDC25A, HSP90AA1, SLC7A11 and SLC1A5 was performed, which confirmed that 10 mg / kg MGCD-265 treatment upregulated the levels of the above proteins.

[0260] Fig.80 : Effects of MGCD-265 combined with SKLB325 on the proliferation ability of gallbladder cancer GBC-SD cells; The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of the concentration of MGCD-265 combined with SKLB325.

[0261] Fig.81 : Effects of MGCD-265 combined with SKLB325 on the proliferation ability of gallbladder cancer NOZ cells; The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of the concentration of MGCD-265 combined with SKLB325.

[0262] Fig.82 : Effects of MGCD-265 combined with SKLB325 on the proliferation ability of gallbladder cancer SGC-996 cells; The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of the concentration of MGCD-265 combined with SKLB325.

[0263] Fig.83: Immunohistochemical staining of JMJD6, CDC25A, HSP90AA1, SLC7A11 and SLC1A5 in tumor tissues of subcutaneous tumor-bearing mice treated with 10 mg / kg MGCD-265; Compared with the control group, 10 mg / kg MGCD-265 treatment upregulated the levels of JMJD6, CDC25A, HSP90AA1, SLC7A11 and SLC1A5.

[0264] Fig.84 : Effects of MGCD-265 combined with NVP-BEP800 on the proliferation ability of gallbladder cancer GBC-SD cells; The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of the concentration of MGCD-265 combined with NVP-BEP800.

[0265] Fig.85 : Effects of MGCD-265 combined with NVP-BEP800 on the proliferation ability of gallbladder cancer NOZ cells; The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of the concentration of MGCD-265 combined with NVP-BEP800.

[0266] Fig.86 : Effects of MGCD-265 combined with NVP-BEP800 on the proliferation ability of gallbladder cancer SGC-996 cells; The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of the concentration of MGCD-265 combined with NVP-BEP800.

[0267] Fig.87 :The effect of MGCD-265 combined with HG106 on the proliferation ability of gallbladder cancer GBC-SD cells; The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of the concentration of MGCD-265 combined with HG106.

[0268] Fig.88 :The effect of MGCD-265 combined with HG106 on the proliferation ability of gallbladder cancer NOZ cells; The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of the concentration of MGCD-265 combined with HG106.

[0269] Fig.89 :The effect of MGCD-265 combined with HG106 on the proliferation ability of gallbladder cancer SGC-996 cells; The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of the concentration of MGCD-265 combined with HG106.

[0270] Fig.90 :The effect of MGCD-265 combined with V-9302 on the proliferation ability of gallbladder cancer GBC-SD cells; The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of the concentration of MGCD-265 combined with V-9302.

[0271] Fig.91 :The effect of MGCD-265 combined with V-9302 on the proliferation ability of gallbladder cancer NOZ cells; The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of the concentration of MGCD-265 combined with V-9302.

[0272] Fig.92 :The effect of MGCD-265 combined with V-9302 on the proliferation ability of gallbladder cancer SGC-996 cells; The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of the concentration of MGCD-265 combined with V-9302.

[0273] Fig.93 : Effects of MGCD-265 combined with NSC95397 on the proliferation ability of gallbladder cancer GBC-SD cells; The proportion of surviving gallbladder cancer GBC-SD cells decreased with the increase of the concentration of MGCD-265 combined with NSC95397.

[0274] Fig.94 :The effect of MGCD-265 combined with NSC95397 on the proliferation ability of gallbladder cancer NOZ cells; The proportion of surviving gallbladder cancer NOZ cells decreased with the increase of the concentration of MGCD-265 combined with NSC95397.

[0275] Fig.95 : Effects of MGCD-265 combined with NSC95397 on the proliferation ability of gallbladder cancer SGC-996 cells; The proportion of surviving gallbladder cancer SGC-996 cells decreased with the increase of the concentration of MGCD-265 combined with NSC95397.

[0276] The inventors inoculated the GBC-SD cell suspension in the logarithmic growth phase into the subcutaneous tissue of the right hind limb of BALB / c nude mice, with an inoculation volume of 100 μL and an inoculation amount of 2×106 cells / mouse. When the tumor volume grew to about 100 mm3, the mice were randomly divided into a control group, an MGCD-265 group (5 mg / kg), a SKLB325 group (5 mg / kg), and a MGCD-265+SKLB325 group. The drug was administered by gavage, 100 μL / mouse. Tumor size and body weight were measured once every 3 days. On the 28th day after treatment, the mice were killed by cervical dislocation, and the tumors were removed and fixed in formalin.

[0277] Collect subcutaneous tumor tissue from mice. Figures 96-98 The statistical results and representative pictures of subcutaneous tumor growth in tumor-bearing mice after treatment with 5 mg / kg MGCD-265 combined with 5 mg / kg SKLB325; the results showed that compared with the use of MGCD-265 alone or SKLB325 alone, the combination of the two can significantly reduce the in vivo growth ability of gallbladder cancer cells.

[0278] Monitor the body weight of mice. Fig.99 The results show that 5 mg / kg of MGCD-265 combined with 5 mg / kg of SKLB325 have no significant effect on the body weight of mice. Although MGCD-265 combined with SKLB325 can reduce the body weight of mice, there is no significant difference.

[0279] 31. Collect subcutaneous tumor tissues from mice and perform immunohistochemical staining of CDK4 and CDK6. Fig.100 This is the immunohistochemical staining of CDK4 and CDK6 in the tumor nodules of tumor-bearing mice after treatment with 5 mg / kg MGCD-265 combined with 5 mg / kg SKLB325; the results showed that compared with the use of MGCD-265 alone or SKLB325 alone, the combination of the two significantly reduced the content of CDK4 and CDK6.

[0280] The liver and kidney tissues of mice were collected, fixed and embedded, and then HE staining was performed. Fig.101 HE staining was used to detect the effect of 5 mg / kg MGCD-265 combined with 5 mg / kg SKLB325 on the liver pathological conditions of tumor-bearing mice; Fig.102 HE staining was used to detect the effect of 5 mg / kg MGCD-265 combined with 5 mg / kg SKLB325 on the renal pathological condition of tumor-bearing mice; the results showed that neither MGCD-265 alone, SKLB325 alone, nor the combination of the two had a significant effect on the liver and kidney pathological morphology of mice.

[0281] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principle of the present invention should be covered by the protection scope of the present invention.

Claims

1. The application of MST1R inhibitor MGCD-265 and JMJD6 inhibitor SKLB325 in the preparation of drugs for the treatment of gallbladder cancer.

2. The use according to claim 1, characterized in that The gallbladder cancer is gallbladder cancer of different species.

3. The use according to claim 1, characterized in that The gallbladder cancer cells are GBC-SD, NOZ, and SGC-996 cells.

4. The use according to claim 1, characterized in that The mouse gallbladder cancer was induced by GBC-SD cells.

5. The use according to claim 1, characterized in that The Q values ​​of MGCD-265 combined with SKLB325 for gallbladder cancer cells GBC-SD, NOZ, and SGC-996 were all greater than 1.

15.

6. The use according to claim 1, characterized in that The combination of MST1R inhibitor and JMJD6 inhibitor reduced the in vitro proliferation ability of GBC-SD, NOZ, SGC-996 cells and other gallbladder cancer cells.

7. The use according to claim 1, characterized in that The combination of MST1R inhibitor and JMJD6 inhibitor reduced the in vivo growth ability of gallbladder cancer cell GBC-SD.

8. The use according to claim 1, characterized in that The combination of MST1R inhibitor and JMJD6 inhibitor reduced the levels of CDK4 and CDK6.

9. The use according to claim 1, characterized in that The drug includes an MST1R inhibitor, a JMJD6 inhibitor and a pharmaceutically acceptable carrier.

10. The use according to claim 1, characterized in that The medicine is an oral or injectable preparation.